Morteza Aghmesheh
Overview
Explore the profile of Morteza Aghmesheh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grimison P, Mersiades A, Kirby A, Tognela A, Olver I, Morton R, et al.
J Clin Oncol
. 2024 Aug;
42(34):4040-4050.
PMID: 39151115
Purpose: The aim of this randomized, placebo-controlled, two-stage, phase II/III trial was to determine the efficacy of an oral cannabis extract in adults with refractory nausea and/or vomiting during moderately...
2.
Bishnoi S, Kotasek D, Aghmesheh M, Yau T, Cosman R, Prawira A, et al.
Cancer
. 2024 Feb;
130(11):1991-2002.
PMID: 38404184
Background: This study investigated the safety and efficacy of an anti-CTLA-4 monoclonal antibody (CS1002) as monotherapy and in combination with an anti-PD-1 monoclonal antibody (CS1003) in patients with advanced/metastatic solid...
3.
Yeo N, Genenger B, Aghmesheh M, Thind A, Napaki S, Perry J, et al.
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894393
Approximately 3-5% of patients with cutaneous squamous cell carcinoma (CSCC) develop advanced disease, accounting for roughly 1% of all cancer deaths in Australia. Immunotherapy has demonstrated significant clinical benefit in...
4.
Haggstrom L, Tucker K, Williams R, Nelson A, Walsh R, Brungs D, et al.
JCO Precis Oncol
. 2023 Sep;
7:e2300221.
PMID: 37725782
No abstract available.
5.
Turner R, Guy T, Geraghty N, Splitt A, Watson D, Brungs D, et al.
Int J Mol Sci
. 2023 Aug;
24(16).
PMID: 37628721
The ectonucleotidases CD39 and CD73 are present on immune cells and play important roles in cancer progression by suppressing antitumour immunity. As such, CD39 and CD73 on peripheral blood mononuclear...
6.
Symons R, Daly D, Gandy R, Goldstein D, Aghmesheh M
Curr Treat Options Oncol
. 2023 Feb;
24(4):241-261.
PMID: 36826686
Small intestine cancer is rare, accounting for approximately 3% of all gastrointestinal malignancies. The most common histological subtypes include adenocarcinoma, neuroendocrine tumours (NETs) and gastrointestinal stromal tumours (GISTs). In localised...
7.
Tincknell G, Naveed A, Nankervis J, Mukhtiar A, Piper A, Becker T, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497236
Brain metastasis from gastroesophageal adenocarcinomas (GOCs) is a rare but a devastating diagnosis. Human epidermal growth factor receptor 2 (HER2) is a prognostic and predictive biomarker in GOCs. The association...
8.
Siu D, ONeill R, Harris C, Wang J, Ardolino L, Downton T, et al.
Immunotherapy
. 2022 Mar;
14(7):511-520.
PMID: 35321560
Immune checkpoint inhibitors have been incorporated into the treatment of various malignancies. An increasing body of literature is reporting rare but potentially fatal adverse events associated with these agents. In...
9.
Siu D, Ali A, Tjokrowidjaja A, De Silva M, Lee J, Clingan P, et al.
Asia Pac J Clin Oncol
. 2022 Jan;
18(6):660-668.
PMID: 35098672
Background: Patients with early-onset colorectal cancer (EO-CRC) have unique characteristics. Contemporary data on the pathological and molecular features, and survival of EO-CRC are limited in the Australian context. Aim: To...
10.
Hope A, Wade S, Aghmesheh M, Vine K
J Control Release
. 2021 Dec;
341:399-413.
PMID: 34863842
Breast cancer remains a leading global cause of morbidity and mortality. While the field of immunotherapy is a promising avenue of investigation and has revolutionized the standard of care for...